Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5821)
All Articles published online
|
Publishing Process of This Article
|
Feb 6, 2015 (publication date) through Apr 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang LT, Park JK. Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 2015; 4(1): 138-147 [PMID: 25664256 DOI: 10.5527/wjn.v4.i1.138] |
|---|---|
| URL: | https://www.wjgnet.com/2220-6124/full/v4/i1/138.htm |
| Number | Citing Articles |
| 1 |
Taymour Mostafa. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. Sexual Medicine Reviews 2016; 4(3): 270 doi: 10.1016/j.sxmr.2015.12.005
|
| 2 |
Kai Sun, Fengze Sun, Huibao Yao, Dongxu Zhang, Gang Wu, Tianqi Wang, Jipeng Wang, JiTao Wu. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. American Journal of Men's Health 2020; 14(6) doi: 10.1177/1557988320980180
|
| 3 |
Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves. Early investigational agents for the treatment of benign prostatic hyperplasia’. Expert Opinion on Investigational Drugs 2024; 33(4): 359 doi: 10.1080/13543784.2024.2326023
|
| 4 |
Igor Voznesensky, Eric Shaw, Kenneth J. DeLay, Faysal Yafi, Wayne J.G. Hellstrom. Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. Sexual Medicine Reviews 2017; 5(1): 87 doi: 10.1016/j.sxmr.2016.05.006
|
| 5 |
Kanika Gupta, Mona Yezdani, Tiffany Sotelo, Jeanny B Aragon-Ching. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs 2015; 24(8): 1059 doi: 10.1517/13543784.2015.1048333
|
| 6 |
Mohamed Mahmoud Zaza, Adham Hussien Mohamed Hussien, Tarek Abdel-Majid Salem, Mohamed Hassan Ali Soliman. The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial. Journal of Clinical Urology 2024; doi: 10.1177/20514158241227097
|
| 7 |
Hakan Öztürk. How close are PDE5 inhibitors to being successful in the treatment of BPH?. The Journal of Clinical Pharmacology 2016; 56(4): 381 doi: 10.1002/jcph.623
|
| 8 |
Taymour Mostafa. Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. Sexual Medicine Reviews 2017; 5(2): 170 doi: 10.1016/j.sxmr.2016.02.004
|
| 9 |
Mohamed Tharwat, Mohamed M. Elsaadany, Ahmed M. Lashin, Ahmed R. EL-Nahas. A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms. World Journal of Urology 2018; 36(11): 1877 doi: 10.1007/s00345-018-2339-y
|
| 10 |
Hamidreza Baghani Aval, Zeinab Ameli, Mojtaba Ameli. Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial. Urologia Journal 2018; 85(2): 51 doi: 10.1177/0391560317749427
|
| 11 |
Robert A. Kloner, Paul Goggin, Irwin Goldstein, Geoffrey Hackett, Michael G. Kirby, Ian Osterloh, John D. Parker, Richard Sadovsky. A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction. Journal of Cardiovascular Pharmacology and Therapeutics 2018; 23(5): 375 doi: 10.1177/1074248418771896
|